Omidian Sajjad, Nazarpak Masoumeh Haghbin, Bagher Zohreh, Moztarzadeh Fathollah
Biomaterials Group, Faculty of Biomedical Engineering (Center of Excellence), Amirkabir University of Technology (Tehran Polytechnic) Tehran Iran.
New Technologies Research Center (NTRC), Amirkabir University of Technology (Tehran Polytechnic) Tehran Iran
RSC Adv. 2025 Jun 3;15(23):18657-18669. doi: 10.1039/d5ra01999k. eCollection 2025 May 29.
This study explores the multifunctional application of vanadium ferrite-doped mesoporous bioactive glass-ceramics (MBGCs), presenting a novel approach to synergistically integrate chemohyperthermia and controlled cisplatin delivery in cancer treatment. Using the sol-gel method, MBGC formulations were developed, which VF0510 (a formulation containing 5 mol% VO and 10 mol% FeO) identified as the optimal composition due to its superior magnetic properties, bioactivity, and controlled drug delivery capabilities. The previously established mesoporous architecture of VF0510, validated in our earlier study, enabled effective cisplatin loading and sustained release in this work. Calorimetric analyses revealed that VF0510 achieved a controlled therapeutic temperature of 41.5 °C under an alternating magnetic field, meeting the optimal range for hyperthermia-based treatments. Drug loading studies demonstrated that hydroxypropyl cellulose (HPC)-coated VF0510 provided a sustained release of 68% over 48 hours, significantly reducing the burst effect while maintaining prolonged therapeutic action. assays using MG63 osteosarcoma cells demonstrated statistically significant results ( < 0.01), with cisplatin-loaded VF0510 reducing cell viability by 45% within 48 hours through apoptosis induction, as confirmed by flow cytometry. This dual-modality platform integrates localized magnetic hyperthermia with controlled chemotherapy delivery, addressing challenges such as systemic toxicity and drug resistance. The results highlight the critical role of vanadium ferrite in enhancing magnetic response and bioactivity, while the HPC coating ensures sustained and efficient drug release. Future research should optimize the thermoresponsive properties of polymer coatings and validate findings through models, paving the way for safer, more effective cancer therapies combining hyperthermia and chemotherapy.
本研究探索了钒铁氧体掺杂介孔生物活性玻璃陶瓷（MBGCs）的多功能应用，提出了一种在癌症治疗中协同整合化学热疗和顺铂控释的新方法。采用溶胶 - 凝胶法制备了MBGC配方，其中VF0510（一种含有5 mol% VO和10 mol% FeO的配方）因其优异的磁性能、生物活性和控释药物能力而被确定为最佳组成。在我们早期研究中验证的VF0510先前建立的介孔结构，使得在本研究中能够实现有效的顺铂负载和持续释放。量热分析表明，VF0510在交变磁场下实现了41.5°C的可控治疗温度，符合基于热疗的治疗的最佳范围。药物负载研究表明，羟丙基纤维素（HPC）包覆的VF0510在48小时内提供了68%的持续释放，显著降低了突释效应，同时保持了延长的治疗作用。使用MG63骨肉瘤细胞的实验显示出具有统计学意义的结果（<0.01），负载顺铂的VF0510通过诱导凋亡在48小时内将细胞活力降低了45%，流式细胞术证实了这一点。这种双模态平台将局部磁热疗与可控化疗递送相结合，解决了全身毒性和耐药性等挑战。结果突出了钒铁氧体在增强磁响应和生物活性方面的关键作用，而HPC涂层确保了持续有效的药物释放。未来的研究应优化聚合物涂层的热响应特性，并通过体内模型验证研究结果，为结合热疗和化疗的更安全、更有效的癌症治疗铺平道路。
